Clene Inc. Overview
CLNN market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
CLNN price chart · 1M
- O
- 4.10
- H
- 4.10
- L
- 3.85
- C
- 3.85
- Vol
- 1,875.00
Daily history from Aug 27, 2018
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $4.10
- Previous Close
- $3.86
- Day High
- $4.10
- Day Low
- $3.85
- 52 Week High
- $10.99
- 52 Week Low
- $3.03
- 7 Day Return
- -1.16%
- 30 Day Return
- -2.04%
- 90 Day Return
- -19.62%
- 1 Year Return
- -61.29%
- Daily Notional Volume
- $7.2K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.65 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.13 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -20,059.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.02 – $11.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $56.1M · P/B 2.84 · P/S 285.00.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
9 captured